{"result": "(\"entity\"<|>CALCITONIN<|>EVENT<|>Calcitonin is a hormone produced by the parafollicular cells of the thyroid, which can serve as a tumor marker in the diagnosis and management of medullary thyroid carcinoma.)\n##\n(\"entity\"<|>MEDULLARY THYROID CARCINOMA<|>EVENT<|>Medullary thyroid carcinoma is a type of thyroid cancer that arises from parafollicular cells and is associated with elevated calcitonin levels.)\n##\n(\"entity\"<|>WELLS<|>PERSON<|>Wells is a researcher who has contributed to the guidelines for the management of medullary thyroid carcinoma and has co-authored significant studies in the field.)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>MEDULLARY THYROID CARCINOMA<|>The American Thyroid Association provides guidelines for the management of medullary thyroid carcinoma<|>8)\n##\n(\"relationship\"<|>MACHENS<|>WELLS<|>Machens and Wells have collaborated on research related to the management of medullary thyroid carcinoma<|>6)\n##\n(\"relationship\"<|>CALCITONIN<|>MEDULLARY THYROID CARCINOMA<|>Elevated calcitonin levels are indicative of medullary thyroid carcinoma<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines\n           Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1-133.                                                     B. Tiroidectomía total y vaciamiento de compartimento VI.\n                                                                                                                                                        C. Tiroidectomía total y vaciamiento ganglionar de compartimentos II al V derechos\n                                                                                                                                                            y compartimento VI.\n                                                                                                                                                        D.  Tiroidectomía total y vaciamiento ganglionar lateral bilateral y central.\n\n\n\n186                                                                                                                                                                                                                                                                                   187\n---\n                                                                                                                                                                                                                                                      TIROIDES                         3\n\n\n\n         COMENTARIO                                                                                                                                         las guías ATA 2015 recomiendan realizar estudios radiológicos más extensos para excluir\n         El paciente presenta adenopatías patológicas en cadena lateral derecha y unos niveles                                                              esta posibilidad (opción B correcta).\n         elevados de calcitonina sérica. Indudablemente, realizar solo tiroidectomía total o acompa-                                                        Referencias:\n         ñarla de linfadenectomía del compartimento central, sin tocar el compartimento lateral que                                                         • Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management\n                                                                                                                                                              of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid.\n         es donde tiene las adenopatías, no sería correcto. Por lo tanto, las dos primeras opciones                                                           2015;25(6):567-610.\n         son falsas.\n         La duda sería si además de realizar el vaciamiento del compartimento lateral afectado, que                                               3.8 Casos clínicos. Caso clínico 3\n         es la opción C a la pregunta, estaría indicado realizar la del compartimento lateral del lado\n         opuesto, que es la opción D.\n         Los niveles preoperatorios de calcitonina ayudan a predecir la extensión de la enfermedad                                                   51     Aunque los niveles de calcitonina plasmática orientarían hacia el diagnóstico, ¿en\n         en el momento del diagnóstico y por lo tanto a la planificación de la cirugía. En el estudio de                                                    qué otras circunstancias pueden estar aumentados? (indique la respuesta falsa):\n         Machens y Dralle encuentran que niveles de calcitonina superiores a 200 pg/ml, como es el\n         caso del paciente descrito, se asocian con la presencia de metástasis ganglionares en las                                                          A. Insuficiencia renal.\n         cadenas laterales contralaterales, siendo su frecuencia mayor cuanto más elevado sea el                                                            B. Tratamiento con betabloqueantes.\n         nivel de calcitonina. Concretamente indican que, si la calcitonina es mayor de 200 pg/ml,la                                                        C. Hipergastrinemia.\n         frecuencia es de un 14%; si es superior a 1.000, de un 18%, y si excede los 2.000, de un 44%.                                                      D.  A y C son causas de elevación de la calcitonina.\n         Basándose en estos            hallazgos, la     Guía ATA      2015    para   el  manejo del cáncer medular de\n         tiroides indica que, en caso de niveles preoperatorios de calcitonina mayores de 200 pg/ml\n         “debería considerarse” realizar linfadenectomía del compartimento contralateral (opción D                                                          COMENTARIO\n         correcta).                                                                                                                                         La calcitonina (CT) es un péptido de 32 aminoácidos, segregado por las células parafoli-\n         Referencias:                                                                                                                                       culares del tiroides, que puede ser utilizado como marcador tumoral para el diagnóstico y\n         • Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab.             seguimiento de los carcinomas medulares de tiroides.\n           2010;95:2655-63.\n         • Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, N, et al. Revised American Thyroid Association Guidelines for the Management            Existe amplia controversia en la literatura científica acerca de su utilidad en el protocolo\n           of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid.\n           2015;25(6):567-610.                                                                                                                              diagnóstico de los nódulos tiroideos, controversia no resuelta en la actualidad. Una de las\n                                                                                                                                                            dificultades para su utilización sistemática en la valoración de los nódulos tiroideos es que\n                                                                                                                                                            la CT puede estar elevada no solo en los carcinomas medulares de tiroides, sino en muchas\n     50  Siguiendo con el caso anterior, si los niveles de calcitonina fuesen superiores a                                                                  otras patologías:       insuficiencia      renal   crónica, mastocitosis,         tiroiditis  linfocitarias, tumores\n         500\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association is a professional organization that provides guidelines for the management of thyroid conditions, including thyroid nodules and differentiated thyroid cancer.)\n##\n(\"entity\"<|>THYROID NODULES<|>EVENT<|>Thyroid nodules are abnormal growths in the thyroid gland that can be benign or malignant, and their management is guided by the American Thyroid Association's recommendations.)\n##\n(\"entity\"<|>DIFFERENTIATED THYROID CANCER<|>EVENT<|>Differentiated thyroid cancer is a type of thyroid cancer that arises from follicular cells and is characterized by specific treatment guidelines set forth by the American Thyroid Association.)\n##\n(\"entity\"<|>MACHENS<|>PERSON<|>Machens is a researcher who has contributed to the understanding of calcitonin levels in relation to thyroid cancer and its management.)\n##\n(\"entity\"<|>DRALLE<|>PERSON<|>Dralle is a researcher who has worked on the management of medullary thyroid carcinoma and has co-authored guidelines with the American Thyroid Association.)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>THYROID NODULES<|>The American Thyroid Association provides guidelines for the management of thyroid nodules<|>8)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>DIFFERENTIATED THYROID CANCER<|>The American Thyroid Association provides guidelines for the management of differentiated thyroid cancer<|>8)\n##\n(\"relationship\"<|>MACHENS<|>DRALLE<|>Machens and Dralle have collaborated on research related to thyroid cancer management<|>6)\n<|COMPLETE|>"}]}